Singapore is only the third country to start recruiting patients as part of a global antibody trial called Activ-3. - ST/ANN
SINGAPORE (The Straits Times/ANN): Hospitalised Covid-19 patients here will now have a new treatment option: to take part in Singapore's first phase three monoclonal antibody trial.
The National Centre for Infectious Diseases (NCID) said that it is ready to enrol its first patients as of Tuesday (Oct 6) - though none had been recruited as at Thursday afternoon - and aims to enrol a total of 100 local patients.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
